FDA Forecast: What’s Next for the FDA in 2022? (On-Demand)

1.0 RAC Credits Member: $0 NonMember: $0
FDA Forecast: What’s Next for the FDA in 2022? (On-Demand)

This is an On-demand recording from December 2021.

Learn how to be more strategic by anticipating and planning for upcoming regulatory changes with FDA by attending this live broadcast, free for RAPS members and nonmembers alike.

Experts from the AgencyIQ regulatory intelligence team will explore challenges and answer questions faced by regulatory affairs professionals, including:
  • Which regulatory changes might happen in 2022?
  • What has the FDA learned from the pandemic, and how might that change how it operates?
  • What might Congress do next year, and how might that affect regulated industry?
  • What topics are likely to receive significant attention from regulators?
In this webcast, the AgencyIQ regulatory intelligence team will explore the top regulatory issues they expect the FDA and life sciences industry to face next year, including what they expect to happen, why they think it will happen, and what it would mean for the life sciences industry.

Learning Objectives

Upon the conclusion of the program you will:
  • Understand key regulatory events and topics that are likely to emerge in 2022.
  • Understand why those events and topics are likely to be important and
  • How the expected challenges might affect life sciences companies

Who should attend?

• Regulatory Intelligence
• Regulatory Policy
• Regulatory Strategy
• Regulatory Affairs (VP, Director, Manager)


Executive Director, Life Sciences

Alexander Gaffney is the Executive Director of Life Sciences at POLITICO’s AgencyIQ, where he leads the team’s research and analysis of life sciences regulatory issues affecting the Food and Drug Administration. Alexander previously worked at PricewaterhouseCoopers where he led analysis of life sciences regulatory issues for the firm’s prestigious Health Research Institute. Before joining PwC, he was the Manager of Regulatory Intelligence at the Regulatory Affairs Professionals Society (RAPS), where he also was Managing Editor of the company’s flagship publication, Regulatory Focus. Alexander has maintained his Regulatory Affairs Certification (RAC) in US regulation since 2013, and also received his master’s degree in regulatory science from the University of Maryland.

Senior Manager

Laura DiAngelo is a Senior Research Manager on the AgencyIQ team. She contributes to the research and development of content for Agency IQ. Before joining POLITICO, Laura consulted on policy and regulatory issues for life sciences and health plan clients with Avalere Health, and managed content for the Avalere Policy and State Reform 360® business intelligence research products. She holds a MPH in health care policy from the George Washington University’s Milken School of Public Health, as well as a BA from Binghamton University. Laura lives in Washington DC, and enjoys the work of the Washington National Opera and the Washington Capitals.

Senior Manager

Kedest Tadesse is a Senior Research Manager and contributes to the research and development of content for AgencyIQ. Prior to joining AgencyIQ, Kedest worked on issues related to the development, regulation, and litigation of foods, drugs and medical devices. She coordinated and compiled regulatory submissions to the FDA. Kedest also provided support in responding to various legislative challenges to consumer and industrial products. Kedest received a B.S. in Biochemistry and Cell Biology from Jacobs University (Bremen, Germany) and a M.S. in Biotechnology from Georgetown University (Washington, DC). Kedest also holds a Regulatory Affairs Certification (RAC) in US regulation.
Add to Cart

Discover more of what matters to you

Regulatory Intelligence/Policy

News »